Clinical Reviews in Bone and Mineral Metabolism

, Volume 8, Issue 1, pp 15–26

Glucocorticoid-Induced Osteoporosis: A Review

Authors

  • Béatrice Bouvard
    • Faculté de MédecineINSERM, U 922–LHEA
    • Service de Rhumatologie
  • Erick Legrand
    • Faculté de MédecineINSERM, U 922–LHEA
    • Service de Rhumatologie
  • Maurice Audran
    • Faculté de MédecineINSERM, U 922–LHEA
    • Service de Rhumatologie
    • Faculté de MédecineINSERM, U 922–LHEA
Original Paper

DOI: 10.1007/s12018-009-9051-9

Cite this article as:
Bouvard, B., Legrand, E., Audran, M. et al. Clinic Rev Bone Miner Metab (2010) 8: 15. doi:10.1007/s12018-009-9051-9

Abstract

Glucocorticoid (GC)-induced osteoporosis is the main cause of secondary osteoporosis. Fractures, which are often asymptomatic, can occur in as many as 50% of patients receiving chronic GC therapy. GCs have direct and indirect effects on bone cells (osteoblasts, osteocytes, and osteoclasts) with a suppression of bone formation and an increased bone resorption. The management of patients exposed to GCs should include the use of the minimal effective dose of GC, general health measures, and adequate intakes of calcium and vitamin D. Bisphosphonates are nowadays largely used in GC-induced osteoporosis and teriparatide has proved its efficiency as well.

Keywords

Glucocorticoid-induced osteoporosis Fractures Bone mineral density Microarchitecture Bone formation Bone resorption Bisphosphonates

Copyright information

© Humana Press Inc. 2009